{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:05:49Z","timestamp":1791108349743,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jinf.2014.03.001","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T19:45:59Z","timestamp":1394739959000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections"],"prefix":"10.1016","volume":"69","author":[{"given":"Nihal","family":"Martis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2014.03.001_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ajic.2004.10.001","article-title":"National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004","volume":"32","author":"National Nosocomial Infections Surveillance System","year":"2004","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jinf.2014.03.001_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective Nationwide Surveillance Study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.amjmed.2008.03.029","article-title":"Incidence of Pseudomonas aeruginosa bacteremia: a population-based study","volume":"121","author":"Al-Hasan","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.jinf.2014.03.001_bib4","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.06365-11","article-title":"Evaluation of clinical outcomes in patients with bloodstream infections due to gram-negative bacteria according to carbapenem MIC stratification","volume":"56","author":"Esterly","year":"2012","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1128\/AAC.01446-09","article-title":"Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa","volume":"54","author":"Tam","year":"2010","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01169-07","article-title":"Clinical and economic impact of common multidrug-resistant gram-negative bacilli","volume":"52","author":"Giske","year":"2008","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib7","unstructured":"Publications \u2013 annual-epidemiological-report-2013.pdf. At: <http:\/\/www.ecdc.europa.eu\/en\/publications\/_layouts\/forms\/Publication_DispForm.aspx?List=4f55ad51%2D4aed%2D4d32%2Db960%2Daf70113dbb90&ID=989&RootFolder=%2Fen%2Fpublications%2FPublications&Web=270275b7%2D419a%2D4352%2Da8fb%2Df0c757d92e66>."},{"key":"10.1016\/j.jinf.2014.03.001_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1592\/phco.2005.25.10.1353","article-title":"Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options","volume":"25","author":"Obritsch","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jinf.2014.03.001_bib9","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/338782","article-title":"Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?","volume":"34","author":"Livermore","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1099\/jmm.0.009142-0","article-title":"Pseudomonas aeruginosa \u2013 a phenomenon of bacterial resistance","volume":"58","author":"Strateva","year":"2009","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jinf.2014.03.001_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/528867","article-title":"Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib12","article-title":"Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009\u20132011)","author":"Sader","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib13","first-page":"273","article-title":"In\u00a0vitro activity of colistin against multidrug-resistant Pseudomonas aeruginosa isolates from patients in Songklanagarind Hospital, Thailand","volume":"44","author":"Tunyapanit","year":"2013","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.jinf.2014.03.001_bib14","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1086\/379611","article-title":"Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa","volume":"37","author":"Linden","year":"2003","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jinf.2014.03.001_bib15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0304-4165(70)90044-9","article-title":"Biosynthesis of colistin by a cell-free system Bacillus colistinus Koyama","volume":"215","author":"Ito","year":"1970","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jinf.2014.03.001_bib16","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jinf.2014.03.001_bib17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-72-6-857","article-title":"Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy","volume":"72","author":"Koch-Weser","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jinf.2014.03.001_bib18","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1128\/iai.64.12.4922-4927.1996","article-title":"Antiendotoxin activity of cationic peptide antimicrobial agents","volume":"64","author":"Gough","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2014.03.001_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s10156-012-0544-y","article-title":"Effects of slow-releasing colistin microspheres on endotoxin-induced sepsis","author":"Nanjo","year":"2013","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/39.2.255","article-title":"A reassessment of the in-vitro activity of colistin sulphomethate sodium","volume":"39","author":"Catchpole","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1345\/aph.18426","article-title":"Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria","volume":"33","author":"Evans","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jinf.2014.03.001_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00865-13","article-title":"Unique structural modifications are present\u00a0in the LPS from colistin-resistant strains of Acinetobacter baumannii","author":"Pelletier","year":"2013","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib24","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/AAC.00103-06","article-title":"Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii","volume":"50","author":"Li","year":"2006","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib25","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1086\/514760","article-title":"Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa","volume":"28","author":"Harris","year":"1999","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jinf.2014.03.001_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/dkh167","article-title":"Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate","volume":"53","author":"Li","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2012.07.010","article-title":"Pharmacokinetics and pharmacodynamics of \u2018old\u2019 polymyxins: what is new?","volume":"74","author":"Bergen","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib28","first-page":"30","article-title":"Colistin pharmacokinetics: the fog is lifting","volume":"18","author":"Couet","year":"2012","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib29","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.00985-12","article-title":"Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration","volume":"57","author":"Karvanen","year":"2013","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib30","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clinthera.2008.01.015","article-title":"Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study","volume":"30","author":"Markou","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.jinf.2014.03.001_bib32","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib33","unstructured":"EUCAST: clinical breakpoints. At: <http:\/\/www.eucast.org\/clinical_breakpoints\/>."},{"key":"10.1016\/j.jinf.2014.03.001_bib34","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1128\/AAC.00903-09","article-title":"Pharmacokinetic\/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in\u00a0vitro model","volume":"54","author":"Bergen","year":"2010","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1128\/AAC.45.3.781-785.2001","article-title":"In\u00a0vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis","volume":"45","author":"Li","year":"2001","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib36","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1128\/AAC.06486-11","article-title":"In\u00a0vivo pharmacokinetics\/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection","volume":"56","author":"Hengzhuang","year":"2012","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib37","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1128\/AAC.00713-12","article-title":"Effect of systemic infection induced by Pseudomonas aeruginosa on the brain uptake of colistin in mice","volume":"56","author":"Jin","year":"2012","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib38","first-page":"25","article-title":"Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients","volume":"54","author":"Le Brun","year":"2002","journal-title":"Eur J Pharm Biophaerm Off J Arbeitsgemeinschaft F\u00fcr Pharm Verfahrenstechnik EV"},{"key":"10.1016\/j.jinf.2014.03.001_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.rmed.2007.10.011","article-title":"Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study","volume":"102","author":"Michalopoulos","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.jinf.2014.03.001_bib40","first-page":"1230","article-title":"Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study","volume":"16","author":"Korbila","year":"2010","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib41","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.10-0463","article-title":"Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration","volume":"138","author":"Imberti","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2014.03.001_bib42","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2014.03.001_bib43","unstructured":"Aerosolized and intravenous colistin in healthy adults \u2013 full text view \u2013 ClinicalTrials.gov. At: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01863719>."},{"key":"10.1016\/j.jinf.2014.03.001_bib44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1179\/joc.2010.22.3.175","article-title":"Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use","volume":"22","author":"Daikos","year":"2010","journal-title":"J Chemother Florence Italy"},{"key":"10.1016\/j.jinf.2014.03.001_bib45","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1128\/AAC.06426-11","article-title":"Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1128\/CMR.00006-08","article-title":"Polymyxins revisited","volume":"21","author":"Landman","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jinf.2014.03.001_bib47","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.49.8.3136-3146.2005","article-title":"Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis","volume":"49","author":"Kasiakou","year":"2005","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib48","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/cis286","article-title":"High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study","volume":"54","author":"Dalfino","year":"2012","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jinf.2014.03.001_bib49","series-title":"Vidal.fr \u2013 La base de donn\u00e9es m\u00e9dicamenteuse des m\u00e9decins lib\u00e9raux","year":"2013"},{"key":"10.1016\/j.jinf.2014.03.001_bib50","series-title":"Drugs@FDA: FDA approved drug products","year":"2013"},{"key":"10.1016\/j.jinf.2014.03.001_bib51","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1345\/aph.19370","article-title":"Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis","volume":"34","author":"Conway","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jinf.2014.03.001_bib52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2110-5820-1-14","article-title":"Renal and neurological side effects of colistin in critically ill patients","volume":"1","author":"Spapen","year":"2011","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jinf.2014.03.001_bib53","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10096-006-0191-2","article-title":"Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria","volume":"25","author":"Falagas","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"10.1016\/j.jinf.2014.03.001_bib54","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijantimicag.2005.09.004","article-title":"Nephrotoxicity of intravenous colistin: a prospective evaluation","volume":"26","author":"Falagas","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2014.03.001_bib55","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/599225","article-title":"Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center","volume":"48","author":"Hartzell","year":"2009","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jinf.2014.03.001_bib56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2334-9-26","article-title":"Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections","volume":"9","author":"Gounden","year":"2009","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib57","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-013-0471-6","article-title":"Colistin is relatively safe in hematological malignancies and hematopoietic stem cell\u00a0transplantation patients","author":"Averbuch","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.jinf.2014.03.001_bib58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3121\/cmr.4.2.138","article-title":"The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature","volume":"4","author":"Falagas","year":"2006","journal-title":"Clin Med Res"},{"key":"10.1016\/j.jinf.2014.03.001_bib59","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/thx.52.11.987","article-title":"Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis","volume":"52","author":"Conway","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2014.03.001_bib60","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2013.09.002","article-title":"Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies","volume":"42","author":"Hu","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2014.03.001_bib61","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijantimicag.2012.12.006","article-title":"\u03b2-Lactam plus aminoglycoside or fluoroquinolone combination versus \u03b2-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis","volume":"41","author":"Vardakas","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2014.03.001_bib62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/cid\/cit223","article-title":"Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort","volume":"57","author":"Pe\u00f1a","year":"2013","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jinf.2014.03.001_bib63","first-page":"816","article-title":"Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies","volume":"14","author":"Petrosillo","year":"2008","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/mdr.2010.0145","article-title":"Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea","volume":"17","author":"Lee","year":"2011","journal-title":"Microb Drug Resist Larchmt N"},{"key":"10.1016\/j.jinf.2014.03.001_bib65","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1128\/AAC.05298-11","article-title":"Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in\u00a0vitro pharmacokinetic\/pharmacodynamic model","volume":"55","author":"Bergen","year":"2011","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1128\/AAC.00689-07","article-title":"Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"52","author":"Pankuch","year":"2008","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.diagmicrobio.2010.01.004","article-title":"Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"67","author":"Pankuch","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib68","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1128\/AAC.01576-06","article-title":"Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain","volume":"51","author":"Cirioni","year":"2007","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib69","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.diagmicrobio.2012.08.014","article-title":"In\u00a0vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method","volume":"74","author":"He","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib70","first-page":"974","article-title":"Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)","volume":"11","author":"Fritsche","year":"2005","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib71","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4103\/0255-0857.83905","article-title":"Polymyxins: antimicrobial susceptibility concerns and therapeutic options","volume":"29","author":"Balaji","year":"2011","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jinf.2014.03.001_bib72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1179\/joc.2003.15.3.235","article-title":"In\u00a0vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa","volume":"15","author":"Giamarellos-Bourboulis","year":"2003","journal-title":"J Chemother Florence Italy"},{"key":"10.1016\/j.jinf.2014.03.001_bib73","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijantimicag.2005.10.012","article-title":"In\u00a0vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units","volume":"27","author":"Timurkaynak","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2014.03.001_bib74","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1179\/joc.2004.16.3.282","article-title":"Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections","volume":"16","author":"Tascini","year":"2004","journal-title":"J Chemother Florence Italy"},{"key":"10.1016\/j.jinf.2014.03.001_bib75","first-page":"189","article-title":"In\u00a0vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit","volume":"21","author":"L\u00f3pez-Fabal","year":"2008","journal-title":"Rev Esp Quimioter Publ Of Soc Esp Quimioter"},{"key":"10.1016\/j.jinf.2014.03.001_bib76","first-page":"32","article-title":"In\u00a0vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics","volume":"5","author":"Rynn","year":"1999","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2014.03.001_bib77","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-013-1875-z","article-title":"In\u00a0vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens","author":"Phee","year":"2013","journal-title":"Eur J Clin\u00a0Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"10.1016\/j.jinf.2014.03.001_bib78","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.05996-11","article-title":"In\u00a0vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates","volume":"56","author":"Vidaillac","year":"2012","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib79","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1128\/JCM.43.10.5085-5090.2005","article-title":"Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions","volume":"43","author":"Hill","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jinf.2014.03.001_bib80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/0255-0857.93020","article-title":"In\u00a0vitro pharmacodynamic properties of colistin methanesulfonate and amikacin against Pseudomonas aeruginosa","volume":"30","author":"Bozkurt-Guzel","year":"2012","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jinf.2014.03.001_bib81","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00750-12","article-title":"Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia","volume":"56","author":"Morata","year":"2012","journal-title":"Antimicrobial Agents Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.jinf.2014.03.001_bib82","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/504485","article-title":"Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia","volume":"43","author":"Linden","year":"2006","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jinf.2014.03.001_bib83","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2014.03.001_bib84","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijantimicag.2012.09.016","article-title":"Difficult-to-treat Gram-negative bone and joint infections: efficacy and safety of prolonged intravenous colistin","volume":"41","author":"Valour","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2014.03.001_bib85","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1534734606291676","article-title":"Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis","volume":"5","author":"Tascini","year":"2006","journal-title":"Int J Low Extrem Wounds"},{"key":"10.1016\/j.jinf.2014.03.001_bib86","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/000992288001901106","article-title":"Bacteremia in patients with cystic fibrosis","volume":"19","author":"McCarthy","year":"1980","journal-title":"Clin Pediatr (Phila.)"},{"key":"10.1016\/j.jinf.2014.03.001_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ppul.22664","article-title":"Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium","volume":"48","author":"Young","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jinf.2014.03.001_bib88","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/jps.23508","article-title":"Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies","volume":"102","author":"Wallace","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jinf.2014.03.001_bib89","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/AAC.47.3.905-909.2003","article-title":"Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in\u00a0vitro pharmacodynamic model","volume":"47","author":"Gunderson","year":"2003","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.jinf.2014.03.001_bib90","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","article-title":"Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates","volume":"31","author":"Samonis","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445314000681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445314000681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:19:15Z","timestamp":1759007955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445314000681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0163445314000681"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2014.03.001","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2014.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}